Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit - Concepedia

Concepedia

Publication | Open Access

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit

DOI Full Paper Access

28

Citations

42

References

2021

Year

Emily Nickles, Bhushan Dharmadhikari, Yating Li, Robert J. Walsh, Liang Piu Koh, Michelle Poon, Lip Kun Tan, Lingzhi Wang, Yvonne Ang, Yugarajah Asokumaran,

Cancer Immunology Immunotherapy

Cancer ImmunosurveillanceMedicineImmunologyTherapeutic VaccineDendritic Cell TherapyImmune Checkpoint InhibitorCancer TreatmentMetastatic Nasopharyngeal CarcinomaImmunotherapyOncologyRadiation OncologyConfers Clinical Benefit

References

	Year	Citations

Page 1

Page 1